IN2011KN04700A - - Google Patents
Download PDFInfo
- Publication number
- IN2011KN04700A IN2011KN04700A IN4700KON2011A IN2011KN04700A IN 2011KN04700 A IN2011KN04700 A IN 2011KN04700A IN 4700KON2011 A IN4700KON2011 A IN 4700KON2011A IN 2011KN04700 A IN2011KN04700 A IN 2011KN04700A
- Authority
- IN
- India
- Prior art keywords
- apcs
- antigen
- assessing
- kits
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- 238000003556 assay Methods 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- 229960000074 biopharmaceutical Drugs 0.000 abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000000412 dendrimer Substances 0.000 abstract 2
- 229920000736 dendritic polymer Polymers 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000005847 immunogenicity Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000011161 development Methods 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 229920000962 poly(amidoamine) Polymers 0.000 abstract 1
- 238000012545 processing Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Manufacturing & Machinery (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17961409P | 2009-05-19 | 2009-05-19 | |
| PCT/US2010/035355 WO2010135394A1 (fr) | 2009-05-19 | 2010-05-19 | Compositions, kits et méthodes de présentation d'antigène in vitro, évaluation de l'efficacité d'un vaccin, et évaluation de l'immunotoxicité d'agents biologiques et de médicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2011KN04700A true IN2011KN04700A (fr) | 2015-07-10 |
Family
ID=43126487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4700KON2011 IN2011KN04700A (fr) | 2009-05-19 | 2010-05-19 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20120129199A1 (fr) |
| EP (2) | EP2432893B1 (fr) |
| CN (2) | CN102459629B (fr) |
| CA (1) | CA2762586C (fr) |
| ES (1) | ES2731343T3 (fr) |
| IN (1) | IN2011KN04700A (fr) |
| WO (1) | WO2010135394A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488902B (zh) * | 2011-11-24 | 2014-06-25 | 清华大学 | 白蛋白修饰的pamam自组装转基因组合物及其制备方法与应用 |
| EP3563872A1 (fr) | 2012-04-05 | 2019-11-06 | Massachusetts Institute Of Technology | Compositions immunostimulatrices et leurs procédés d'utilisation |
| WO2014120804A1 (fr) * | 2013-01-30 | 2014-08-07 | University Of Miami | Nanoparticules entériques revêtues pour l'administration par voie orale de vaccins et de médicament, leurs procédés de fabrication et d'utilisation |
| US20140287438A1 (en) * | 2013-03-15 | 2014-09-25 | South Dakota Board Of Regents | Rapid and Inexpensive Assay for Evaluation of Antibody Efficacy with Custom-Designed Fluorescent Nanoparticles |
| EP2972363B1 (fr) * | 2013-03-15 | 2019-10-09 | University Of Miami | Nanovecteurs pour médicaments à effet de potentialisation immunitaire |
| US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| KR20250111403A (ko) | 2018-03-02 | 2025-07-22 | 엘리시오 테라퓨틱스, 인크. | Cpg 양친매성 물질 및 이의 용도 |
| JP2022525781A (ja) | 2019-03-20 | 2022-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫細胞療法における両親媒性物質の使用およびそのための組成物 |
| CN110201192B (zh) * | 2019-06-05 | 2021-08-31 | 东华大学 | 一种树状大分子包裹纳米金颗粒探针及其制备和应用 |
| CN111172195A (zh) * | 2020-02-13 | 2020-05-19 | 翁炳焕 | 一种新冠肺炎基因治疗制品的制备方法 |
| WO2021215952A1 (fr) | 2020-04-24 | 2021-10-28 | Общество С Ограниченной Ответственностью "Индженик" | Procédé de production de particules de bactériophages de la famille levivirus |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2409258A1 (fr) | 1977-11-21 | 1979-06-15 | Rhone Poulenc Ind | Nouvelles compositions a base d'aminoalcoxyamines |
| ES2318848T3 (es) * | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. |
| CA2184132C (fr) * | 1995-09-21 | 2011-03-15 | Kristina J. Hennessy | Vaccin avec adjuvant, pratiquement exempt d'albumine non-hote |
| US5795582A (en) | 1996-02-07 | 1998-08-18 | Novavax, Inc. | Adjuvant properties of poly (amidoamine) dendrimers |
| US6962790B1 (en) * | 1998-09-23 | 2005-11-08 | University Of Massachusetts Medical Center | Predictive assay for immune response |
| AR021849A1 (es) * | 1998-09-30 | 2002-08-07 | Corixa Corp | Composiciones y metodos para la inmunoterapia especifica de wt1 |
| HK1039749B (zh) * | 1998-10-05 | 2007-10-05 | 法麦克萨有限公司 | Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用 |
| US7807377B2 (en) * | 1998-10-20 | 2010-10-05 | Salvatore Albani | Method of isolating antigen-specific T cells employing artificial antigen presenting cells |
| US20040241842A1 (en) * | 1999-04-15 | 2004-12-02 | Monash University | Stimulation of thymus for vaccination development |
| AU7404800A (en) | 1999-09-30 | 2001-04-30 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
| US6632435B1 (en) * | 1999-10-20 | 2003-10-14 | City Of Hope | CTL epitope analogs |
| AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| CA2476995A1 (fr) * | 2001-09-18 | 2003-03-27 | Kyogo Itoh | Procede de detection de l'immunite cellulaire et son application sur des medicaments |
| US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| AU2003208314A1 (en) * | 2002-03-11 | 2003-09-22 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| CN1809379A (zh) * | 2003-04-18 | 2006-07-26 | 诺伍德免疫学有限公司 | 先于胸腺再活化的疾病预防和疫苗接种 |
| JP3101496U (ja) * | 2003-07-23 | 2004-06-10 | 鴻海精密工業股▲ふん▼有限公司 | コネクタ用取り外しツール |
| US7709611B2 (en) * | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
| CN101506266A (zh) * | 2005-02-01 | 2009-08-12 | 梅迪沃什有限公司 | 疫苗输送组合物及使用方法 |
| DK2023952T3 (en) * | 2006-05-18 | 2015-10-19 | Epimmune Inc | Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions |
| CN101711360A (zh) * | 2007-03-16 | 2010-05-19 | 赛乐思迪斯有限公司 | 细胞介导的免疫应答检验及其试剂盒 |
| US9764012B2 (en) * | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
-
2010
- 2010-05-19 IN IN4700KON2011 patent/IN2011KN04700A/en unknown
- 2010-05-19 US US13/321,521 patent/US20120129199A1/en not_active Abandoned
- 2010-05-19 CA CA2762586A patent/CA2762586C/fr not_active Expired - Fee Related
- 2010-05-19 ES ES10778304T patent/ES2731343T3/es active Active
- 2010-05-19 EP EP10778304.5A patent/EP2432893B1/fr not_active Not-in-force
- 2010-05-19 CN CN201080029414.7A patent/CN102459629B/zh not_active Expired - Fee Related
- 2010-05-19 EP EP19171881.6A patent/EP3611270B1/fr not_active Not-in-force
- 2010-05-19 WO PCT/US2010/035355 patent/WO2010135394A1/fr not_active Ceased
- 2010-05-19 CN CN201910689721.0A patent/CN110542754A/zh active Pending
-
2016
- 2016-10-05 US US15/286,131 patent/US20170146526A1/en not_active Abandoned
-
2018
- 2018-12-20 US US16/228,050 patent/US20190170742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170146526A1 (en) | 2017-05-25 |
| EP2432893A4 (fr) | 2013-06-19 |
| CN102459629A (zh) | 2012-05-16 |
| CA2762586C (fr) | 2018-06-19 |
| US20120129199A1 (en) | 2012-05-24 |
| US20190170742A1 (en) | 2019-06-06 |
| CN110542754A (zh) | 2019-12-06 |
| CN102459629B (zh) | 2019-08-27 |
| CA2762586A1 (fr) | 2010-11-25 |
| EP3611270B1 (fr) | 2021-12-01 |
| ES2731343T3 (es) | 2019-11-15 |
| EP2432893B1 (fr) | 2019-05-01 |
| EP3611270A1 (fr) | 2020-02-19 |
| WO2010135394A1 (fr) | 2010-11-25 |
| EP2432893A1 (fr) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2011KN04700A (fr) | ||
| EP2413964A4 (fr) | Compositions vaccinales et leurs procédés d'utilisation | |
| Sheppard et al. | Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens | |
| EA201892021A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| EA201891759A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| JP2014523406A5 (fr) | ||
| Fratzke et al. | Subunit vaccines using TLR triagonist combination adjuvants provide protection against Coxiella burnetii while minimizing reactogenic responses | |
| Cho et al. | Design of immunogenic and effective multi-epitope DNA vaccines for melanoma | |
| Iwama et al. | Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice | |
| WO2022013609A1 (fr) | Compositions de vaccin contre le sars-cov-2 et leurs procédés de préparation et d'utilisation | |
| McElhaney | Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response | |
| Jan et al. | Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge | |
| Woodworth et al. | MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates | |
| DK2066341T3 (en) | PROCEDURE FOR INITIATING OR INDUCING AN IMMUNE RESPONSE | |
| Chang et al. | A novel vaccine adjuvant for recombinant flu antigens | |
| AU2023202175A1 (en) | Self-assembling peptide scaffold | |
| Thueng-in et al. | Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines | |
| Buaklin et al. | Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein | |
| Rahman | Metabolomics for Personalized Vaccinology | |
| Zimmerman et al. | Lessons from next generation influenza vaccines for inflammatory disease therapies | |
| Li et al. | PRR adjuvants restrain high stability peptides presentation on APCs | |
| US20220023412A1 (en) | Compositions Useful in Both Homologous And Heterologous Vaccine Regimens | |
| Jan | Vaccine-induced adaptive T cell immunity enhances protective responses against Coxiella burnetii | |
| CN105530957A (zh) | CpG寡脱氧核苷酸、包含其的免疫组合物及制备组合物并通过其刺激免疫反应的方法 | |
| Lemmon et al. | KITS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS |